[6] Regulatory bodies including the MHRA and EMA have included pancreatitis as a potential adverse effect in the prescribing information for GLP-1 agonists
No clinical evidence supports this concern
A similar effect may be seen in rats with vesicovaginalis fistula, i.e., macro/microscopic recovery, counteracted stone formation, and functional recovery (elimination of vaginal leakingrepresented by the ability to maintain a five-fold-larger volume before leakingin comparison with controls) [118]
For a time, they became popular alternatives to earlier growth hormonereleasing peptides (GHRPs) like GHRP-2 and GHRP-6, especially as regulatory scrutiny increased around those older compounds
[9] It seems unlikely that a step therapy or fail-first program would be considered a wellness program, but if a group health plan implements additional requirements and rewards for participation, the wellness program rules under HIPAA and the ADA may apply